Condition
Lateral Canthal Lines (LCL)
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Completed3
Not Yet Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07492277RecruitingPrimary
A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines
NCT07388927Phase 4Not Yet Recruiting
A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A
NCT04985916Phase 2CompletedPrimary
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
NCT04247074Phase 3Completed
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
NCT03912805Phase 2CompletedPrimary
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Showing all 5 trials